Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures
NCT03678753Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Oct 2018
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in generalized tonic-clonic seizure (GTCS) and idiopathic generalized epilepsy (IGE) comparing Cenobamate with Placebo (2 arms). Primary endpoint: Frequency of Primary Generalized Tonic-Clonic (PGTC) Seizures at 22 weeks. Started Oct 2018; status: completed.
02
Drugs
cenobamate
03
Conditions
generalized tonic-clonic seizure (GTCS)idiopathic generalized epilepsy (IGE)
Beyond the preview
Go deeper on NCT03678753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678753.